InvestorsHub Logo
Followers 33
Posts 2841
Boards Moderated 2
Alias Born 10/24/2015

Re: None

Tuesday, 06/20/2023 6:35:12 PM

Tuesday, June 20, 2023 6:35:12 PM

Post# of 394
(OT): ''The high-affinity and non-cleavable CD16 (hnCD16) is developed and demonstrated a multi-tumor killing potential. However, the hnCD16 receptor activates a single CD16 signal and provides limited tumor suppression. How to exploit the properties of hnCD16 and incorporate NK cell-specific activation domains is a promising development direction to further improve the anti-tumor activity of NK cells.'' https://jhoonline.biomedcentral.com/articles/10.1186/s13045-023-01455-z
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent FATE News